Results 91 to 100 of about 983,540 (218)
COVID arm as a common cutaneous manifestation after mRNA-1273 vaccination: a systematic review
BMC Infectious Diseases, 2023 Background By August 2022, CoronaVirus Disease-2019 (COVID-19) had caused 600 million illnesses and 6.5 million fatalities globally. A massive vaccination program is being implemented worldwide to suppress this condition.
Maulidina Agustin +2 more
doaj +1 more source
The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity [PDF]
, 2021 mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging ...
Carolis, Carlo +10 more
core +1 more source
bioRxiv, 2021 The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike
V. Edara +31 more
semanticscholar +1 more source
Neutralizing antibodies against SARS-CoV-2 of vaccinated healthcare workers in Taiwan
Annals of MedicineBackground Vaccination is one of the best ways to control the SARS-CoV-2 outbreak. In Taiwan, healthcare workers were prioritized for vaccination, but the effectiveness of these vaccines for them remains unclear.
Seto Priyambodo +5 more
doaj +1 more source
Immunity, Inflammation and Disease, 2023 Background and Objectives Since publishing successful clinical trial results of mRNA coronavirus disease 2019 (COVID‐19) vaccines in December 2020, multiple reports have arisen about cardiovascular complications following the mRNA vaccination. This study
Farah Yasmin +12 more
doaj +1 more source
Frontiers in Cellular and Infection Microbiology, 2022 IntroductionSince the COVID-19 outbreak, specific mRNA-based anti-SARS-CoV-2 vaccines have been developed and distributed worldwide. Because this is the first time that mRNA vaccines have been used, there are several questions regarding their capacity to
Sergio Gil-Manso +76 more
doaj +1 more source
Vaccine, 2021 Background Vaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike ...
L. Chu +6 more
semanticscholar +1 more source
Risk of herpes zoster following mRNA COVID-19 vaccine administration
Expert Review of Vaccines, 2023 Background Adverse events following mRNA COVID-19 vaccines, including herpes zoster (HZ), have been reported. We conducted a cohort study to evaluate the association between mRNA COVID-19 vaccination and subsequent HZ at Kaiser Permanente Southern ...
Ana Florea +7 more
doaj +1 more source
Vaccines, 2022 The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2.
Farah M. Shurrab +13 more
doaj +1 more source
Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain [PDF]
Objective: This study aimed to evaluate the effectiveness of SARS-CoV-2 mRNA vaccines in preventing infection and hospitalization among healthcare workers (HCWs) in the Valencian Community (Spain), considering vaccination timing, dose number, and ...
Berenguer, Ana +10 more
core +1 more source